Milnacipran modified-release - Collegium Pharmaceutical
Alternative Names: COL-007Latest Information Update: 02 Oct 2021
At a glance
- Originator Collegium Pharmaceutical; Cypress Bioscience
- Developer Collegium Pharmaceutical
- Class Amides; Amines; Analgesics; Antidepressants; Cyclopropanes; Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Fibromyalgia
Most Recent Events
- 20 Mar 2014 Discontinued for Fibromyalgia in USA (PO)
- 01 Apr 2010 Collegium Pharmaceutical's modified-release milnacipran is available for licensing (http://www.collegiumpharma.com)
- 01 Apr 2010 Investigation in Fibromyalgia in USA (PO)